title: Sofosbuvir-based treatment regimens: real life results of 14 409 chronic HCV genotype 4 patients in Egypt.
abstract: Chronic hepatitis C virus infection is one of the most important health problems in Egypt. The Ministry of Health's National Treatment Programme introduced sofosbuvir-based therapy in October 2014.
  
  
  
  To assess the clinical effectiveness and predictors of response to SOF-based treatment regimens, either dual therapy, with SOF/ribavirin (RBV) for 6 months or triple therapy with SOF/peg-IFN-alfa-2a/RBV for 3 months, in a cohort of patients treated in National Treatment Programme affiliated centres in Egypt.
  
  
  
  Between October 2014 and end of 2014, patients who were eligible for treatment were classified according to their eligibility for interferon therapy: Group 1 (interferon eligible) were treated with triple therapy for 12 weeks and Group 2 (interferon ineligible) were treated with dual therapy for 24 weeks. Difficult to treat patients included those with F3-F4 on Metavir score, Fib-4 >3.25, albumin ≤3.5, total Bilirubin >1.2 mg/dL, INR >1.2 and platelet count <150 000 mm3.
  
  
  
  Twelve weeks post-treatment data were available on 14 409 patients; 8742 in group 1 and 5667 in group 2. In group 1, the sustained virological response at week 12 (SVR12) was 94% and in group 2 the SVR12 was 78.7%. Multivariate logistic regression analysis in which treatment failure is the dependent variable was done. Male gender, being a difficult to treat patient and previous interferon therapy were significant predictors of nonresponse in both treatment groups.
  
  
  
  Results of sofosbuvir-based therapies in Egypt achieved similar rates of SVR12 as seen in phase III efficacy studies.
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: A
authors.initials: A
authors.lastname: Elsharkawy
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: R
authors.initials: R
authors.lastname: Fouad
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: W
authors.initials: W
authors.lastname: El Akel
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: M
authors.initials: M
authors.lastname: El Raziky
authors.affiliation: Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt.
authors.forename: M
authors.initials: M
authors.lastname: Hassany
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansora, Egypt.
authors.forename: G
authors.initials: G
authors.lastname: Shiha
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: M
authors.initials: M
authors.lastname: Said
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Menia University, Minia, Egypt.
authors.forename: I
authors.initials: I
authors.lastname: Motawea
authors.affiliation: Tropical Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
authors.forename: T
authors.initials: T
authors.lastname: El Demerdash
authors.affiliation: Tropical Medicine Department, National Hepatology & Tropical Medicine Research Institute, Cairo, Egypt.
authors.forename: S
authors.initials: S
authors.lastname: Seif
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: A
authors.initials: A
authors.lastname: Gaballah
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: Y
authors.initials: Y
authors.lastname: El Shazly
authors.affiliation: Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
authors.forename: M A M
authors.initials: MA
authors.lastname: Makhlouf
authors.affiliation: Department of Hepatology, National Liver Institute, Menoufyia University, Menoufyia, Egypt.
authors.forename: I
authors.initials: I
authors.lastname: Waked
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: A O
authors.initials: AO
authors.lastname: Abdelaziz
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: A
authors.initials: A
authors.lastname: Yosry
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: M
authors.initials: M
authors.lastname: El Serafy
authors.affiliation: Department of Hepatology, Imperial College London, London, UK.
authors.forename: M
authors.initials: M
authors.lastname: Thursz
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: W
authors.initials: W
authors.lastname: Doss
authors.affiliation: Endemic Medicine and Hepatogastroentrology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
authors.forename: G
authors.initials: G
authors.lastname: Esmat
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004534:Egypt; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011994:Recombinant Proteins / Q000008:administration & dosage; D012189:Retrospective Studies; D012254:Ribavirin / Q000008:administration & dosage / Q000627:therapeutic use; D000069474:Sofosbuvir / Q000008:administration & dosage*
chemical_list: D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a; D000069474:Sofosbuvir